Payment overview · 2025
General Payments
$1,518.34
78 reported records · 26 companies
Healthcare provider profile · identity verified
Robert Pozzi, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SAINT LOUIS, MO · NPI 1518948900
Verified facts
What the public records show
CMS Open Payments records show Robert Pozzi, D.O. received $1,518.34 in general payments during 2025 across 78 reported records.
GlaxoSmithKline, LLC. accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $216.74 | 14.3% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $182.64 | 12.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $110.10 | 7.2% | 6 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $100.80 | 6.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.67 | 6.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $95.12 | 6.3% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $94.21 | 6.2% | 4 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $73.39 | 4.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.74 | 4.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.00 | 4.0% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $51.45 | 3.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.69 | 2.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.61 | 2.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.98 | 2.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.02 | 2.0% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $27.40 | 1.8% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $26.60 | 1.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.56 | 1.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $20.03 | 1.3% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.09 | 1.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.68 | 1.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.26 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.38 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.63 | 1.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $15.03 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.52 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,518.34 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $147.59 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $147.59 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $125.64 | 8 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $125.64 | 8 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $100.80 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $95.12 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $94.21 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $91.10 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.05 | 4 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $73.39 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $73.03 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.24 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $51.45 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.69 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.36 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.43 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.59 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.41 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $27.40 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $26.39 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 118 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 153 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
118 | 116 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
153 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 478 | 134 |
| Lisinopril | Lisinopril | 363 | 99 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 285 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 78 |
| Alprazolam | Alprazolam | 260 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 224 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 59 |
| Metformin Hcl | Metformin Hcl | 167 | 47 |
| Ozempic | Semaglutide | 153 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 39 |
| Tramadol Hcl | Tramadol Hcl | 143 | 49 |
| Losartan Potassium | Losartan Potassium | 139 | 39 |
| Omeprazole | Omeprazole | 133 | 34 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 118 | 116 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 17 |
| Trazodone Hcl | Trazodone Hcl | 112 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 31 |
| Metformin Hcl Er | Metformin Hcl | 111 | 30 |
| Lorazepam | Lorazepam | 101 | 23 |
| Allopurinol | Allopurinol | 100 | 28 |
| Eliquis | Apixaban | 99 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 29 |
| Meloxicam | Meloxicam | 93 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 17 |
| Gabapentin | Gabapentin | 90 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 35 |
| Sertraline Hcl | Sertraline Hcl | 83 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 20 |
| Simvastatin | Simvastatin | 73 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 22 |
| Jardiance | Empagliflozin | 70 | suppressed |
| Furosemide | Furosemide | 66 | 24 |
| Diazepam | Diazepam | 58 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 18 |
| Prednisone | Prednisone | 56 | 44 |
| Carvedilol | Carvedilol | 53 | 18 |
| Famotidine | Famotidine | 50 | 20 |
| Ibuprofen | Ibuprofen | 49 | 12 |
| Montelukast Sodium | Montelukast Sodium | 48 | 13 |
| Spironolactone | Spironolactone | 46 | 12 |
| Bupropion Xl | Bupropion Hcl | 45 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 13 |
| Alendronate Sodium | Alendronate Sodium | 41 | 13 |
| Amoxicillin | Amoxicillin | 41 | 30 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Finasteride | Finasteride | 37 | 11 |
| Azithromycin | Azithromycin | 36 | 27 |
| Temazepam | Temazepam | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 26 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 12 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Baclofen | Baclofen | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Insulin Aspart | Insulin Aspart | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Benzonatate | Benzonatate | 15 | 11 |
| Fluconazole | Fluconazole | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Etodolac | Etodolac | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Micardis Hct | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,518.34 · 78 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, APRETUDE, AREXVY, Auvelity, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, JARDIANCE, LEQVIO, MONOFERRIC, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Omnipod, Ozempic, PREVNAR 20, PROCLAIM, QULIPTA, REPATHA, SHINGRIX, SPRAVATO, Symbravo, TAVNEOS, TRELEGY ELLIPTA, TRINTELLIX, VRAYLAR, VYEPTI, VYNDAQEL, WatchPATONE, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error